No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ZYME240517P10000
- 0.95
- -0.25-20.83%
15min DelayTrading May 13 12:57 ET
0.95High0.95Low
0.95Open1.20Pre Close3 Volume33 Open Interest10.00Strike Price285.00Turnover287.55%IV0.11%PremiumMay 17, 2024Expiry Date0.96Intrinsic Value100Multiplier4DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type-0.5598Delta0.1372Gamma9.52Leverage Ratio-0.1340Theta-0.0008Rho-5.33Eff Leverage0.0039Vega
Intraday
- 5D
- 1D
News
Stifel Nicolaus Reaffirms Their Buy Rating on Zymeworks (ZYME)
Zymeworks Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
Ratings for Zymeworks (NASDAQ:ZYME) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.The table below offers a condensed view of their recent r
Express News | HC Wainwright & Co. Reiterates Neutral on Zymeworks, Maintains $10 Price Target
Zymeworks Price Target Cut to $16.00/Share From $17.00 by Citigroup
Zymeworks Price Target Cut to $16.00/Share From $17.00 by Citigroup
Zymeworks Is Maintained at Overweight by Wells Fargo
Zymeworks Is Maintained at Overweight by Wells Fargo
Express News | Wells Fargo Maintains Overweight on Zymeworks, Lowers Price Target to $12
Comments
See Biotech companies with cancer assets 👇
⇨ held by 5 biopharma-focused hedge funds! 🔥
$Arcellx(ACLX.US$ : Anito-cel (Ph 2)
$Adaptimmune Therapeutics(ADAP.US$ : Afami-cel (PDUFA) ⏳
$Bicycle Therapeutics(BCYC.US$ : BT8009 (Ph 1/2)
$Centessa Pharmaceuticals(CNTA.US$ : LB101 (Ph 1/2)
$Day One Biopharmaceuticals(DAWN.US$ : Tovorafenib (PDUFA) (check comments for details)
$Fate Therapeutics(FATE.US$ : FT576 (Ph 1)
$Fusion Pharmaceuticals(FUSN.US$ : FPI-2265 (Ph 2)
$GRCL: ...
⇨ held by 5 biopharma-focused hedge funds! 🔥
$Arcellx(ACLX.US$ : Anito-cel (Ph 2)
$Adaptimmune Therapeutics(ADAP.US$ : Afami-cel (PDUFA) ⏳
$Bicycle Therapeutics(BCYC.US$ : BT8009 (Ph 1/2)
$Centessa Pharmaceuticals(CNTA.US$ : LB101 (Ph 1/2)
$Day One Biopharmaceuticals(DAWN.US$ : Tovorafenib (PDUFA) (check comments for details)
$Fate Therapeutics(FATE.US$ : FT576 (Ph 1)
$Fusion Pharmaceuticals(FUSN.US$ : FPI-2265 (Ph 2)
$GRCL: ...
9
Read more